Medically Reproducing Bariatric Surgery

NCT03225209 on ClinicalTrials.gov · last registry update 2020-01-31

A small phase 2 — 5 participants, against a typical 110. The sponsor logged completion for 23 October 2018. Primary outcome, as filed: Change in Glycemic control. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Moahad S Dar
Sponsor type: Other
Enrollment: 5
Started: 2018-01-31
Primary completion: 2018-10-23 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Glycemic control

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.